Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of “Hold” from Analysts

Plus Therapeutics, Inc. (NASDAQ:PSTV) has earned a consensus rating of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $56.40.

A number of equities analysts recently commented on PSTV shares. Ascendiant Capital Markets dropped their price objective on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Monday, June 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Friday, July 17th.

Plus Therapeutics Price Performance

Shares of PSTV stock opened at $3.86 on Monday. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The stock’s 50-day moving average is $4.30 and its two-hundred day moving average is $5.56. The firm has a market cap of $26.57 million, a P/E ratio of -1.68 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last posted its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). The firm had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%. As a group, research analysts expect that Plus Therapeutics will post -3.76 EPS for the current year.

Institutional Investors Weigh In On Plus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. L1 Global Manager Pty Ltd bought a new stake in Plus Therapeutics in the fourth quarter worth $1,167,000. Geode Capital Management LLC raised its holdings in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares in the last quarter. Jane Street Group LLC bought a new position in Plus Therapeutics during the fourth quarter valued at about $525,000. Virtu Financial LLC bought a new position in Plus Therapeutics during the fourth quarter valued at about $254,000. Finally, State Street Corp lifted its position in shares of Plus Therapeutics by 37.1% in the fourth quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after buying an additional 127,000 shares during the last quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.